CTRI/2021/06/033958
Not yet recruiting
Phase 1
Proof of concept study to evaluate possibility of reversal in clinically diagnosed brain death subjects following road traffic accident having diffuse axonal injury by extending aggressive critical care for 15 days along with laser and electric stimulation
Himanshu Bansal Foundation0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Health Condition 1: - Health Condition 2: S062- Diffuse traumatic brain injuryHealth Condition 3: S062- Diffuse traumatic brain injuryHealth Condition 4: S062- Diffuse traumatic brain injury
- Sponsor
- Himanshu Bansal Foundation
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Both male and female, Age between 18 to 65 years old.
- •Individuals declared Brain dead from a traumatic brain injury having
- •diffuse axonal injury on MRI
- •Not willing for organ donation
- •Written informed consent from the legally acceptable representative of the patient
Exclusion Criteria
- •Metallic clips/ metal implants or intracranial implants in the brain.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Benralizumab in Severe AsthmaSevere Eosinophilic AsthmaMedDRA version: 21.1Level: LLTClassification code 10068462Term: Eosinophilic asthmaSystem Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2019-003763-22-GBTayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside18
Active, not recruiting
Phase 1
A Proof of Concept Study to Investigate the use of Simvastatin as a Putative Anti-inflammatory Agent in Asthma - Simvastatin in AsthmaAsthmaEUCTR2005-001466-14-GBniversity of Dundee20
Active, not recruiting
Phase 3
The effect of dupilumab on airway twitchiness in severe asthmaAdult patients with severe asthma with type 2 inflammationRespiratoryISRCTN70810039niversity of Dundee20
Active, not recruiting
Not Applicable
Proof of concept study to investigate the impact of BAY 58-2667 given intravenously in patients with acute decompensated chronic congestive heart failureEUCTR2005-004473-14-DEBayer HealthCare AG60
Completed
Phase 2
A prospective *proof of concept study* to evaluate the potential efficacy of ustekinumab in patients with moderate to severe hidradenitis suppurativa (acne ectopica)hidradenitis suppurativaacne ectopicaacne inversa10040798NL-OMON37989niversitair Medisch Centrum Groningen20